Why Is NVO Stock Falling Pre-Market Today?

• The company stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.
• People treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg, according to Novo.
• When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.

Novo Nordisk AS (NVO) shares fell more than 14% in Monday’s pre-market trade after the company announced headline results from Redefine 4, an open-label phase 3 trial.

Novo Nordisk stated that CagriSema demonstrated 23% weight loss in people with obesity, but it failed to meet its primary endpoint.

Retail sentiment on Stocktwits around Novo Nordisk trended in the ‘extremely bearish’ territory at the time of writing.

CagriSema Fails To Match Tirzepatide In Effectiveness

Novo Nordisk stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.

The company said that people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg.

When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.

“CagriSema has the potential to be the first GLP-1/amylin-combination product to reach the market for people living with obesity, documenting that cagrilintide adds to the existing benefits of semaglutide and offers clinically meaningful additive weight loss effects superior to what has been observed with GLP-1 biology alone,” said Novo Nordisk’s Chief Scientific Officer and Executive Vice President, Martin Holst Lange.

Who Is CagriSema Aimed At?

CagriSema is a once-weekly subcutaneous treatment that is being investigated by Novo Nordisk for adults with overweight or obesity issues. It is also being considered as a treatment for adults with type 2 diabetes.

The treatment is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg.

Novo Nordisk says CagriSema works by inducing weight loss by reducing hunger, increasing feelings of fullness, which helps people eat less and reduce their calorie intake.

NVO stock is down 7% year-to-date and 46% over the past 12 months.

Also See: Trump Administration Can Replicate Most Of The Tariffs, Says Goldman Sachs Following Supreme Court Rebuke: Report

For updates and corrections, email newsroom[at]stocktwits[dot]com.